LDAcoop : Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Year: 2025
Type: article
Abstract: The limiting dilution assay (LDA) is a key method to quantify clonogenic cells with self-renewing capacity in vitro, crucial for preclinical cancer research and therapy response assessment. It estimates the frequency of individual clonogenic, stem-like cells within a population based on their ability to form colonies with ≥50 cells at limiting cell numbers. Standard LDA analysis relies on linear, single-hit Poisson models, yet clonogenic growth under single-cell conditions often involves cooperative or competitive dynamics, violating this linearity assumption. Here, we present a modeling framework incorporating non-linear population dynamics into LDA analysis and introduce LDAcoop, an R-based tool for universal quantification of clonogenic cells in LDA formats. Across multiple cancer cell types, we benchmarked LDA against the colony formation assay (CFA) and show that LDA outperforms CFA, especially for patient-derived organoids, suspension cultures, and higher throughput applications. This renders the LDA format particularly suitable for larger-scale pharmacogenomic screening and drug sensitivity testing in complex models. Our results establish LDA and LDAcoop as versatile, scalable tools for robust quantification of clonogenic growth, supporting preclinical drug development and molecular precision oncology research.
Source: Molecular Oncology
Institutions: LMU Klinikum, Ludwig-Maximilians-Universität München, Heidelberg University, University Hospital Heidelberg, Helmholtz Munich, German Center for Diabetes Research, National Institute of Pharmaceutical Education and Research, National Institute of Pharmaceutical Education and Research, Deutsches Konsortium für Translationale Krebsforschung
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,300
Awards: Verbundprojekt METABOLiST: Einfluss veränderter Stoffwechselwege auf die therapeutische Strahlenantwort von Tumoren, Teilprojekt A, Verbundprojekt SeniRad: Strahlungsinduzierte Seneszenz: Implikationen für Normalgewebstoxizität und Tumortherapie-Versagen, Teilprojekt A, STRATUM: Bedeutung metabolischer Subtypen in Tumoren für die therapeutische Strahlenantwort, G6555415023, Verbundprojekt METABOLiST: Einfluss veränderter Stoffwechselwege auf die therapeutische Strahlenantwort von Tumoren, Teilprojekt C, Verbundprojekt ZiSStrans: Zielstrukturen der individuellen Strahlenempfindlichkeit, Teilprojekt A, Verbundprojekt ZiSStrans: Zielstrukturen der individuellen Strahlenempfindlichkeit, Teilprojekt C, Verbundprojekt SeniRad: Strahlungsinduzierte Seneszenz: Implikationen für Normalgewebstoxizität und Tumortherapie-Versagen, Teilprojekt B
OpenAlex ID: W7117368179
